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OBJECTIVES The aim of this study was to determine echocardiographic predictors of outcome in patients
with advanced heart failure (HF) due to severe left ventricular (LV) systolic dysfunction in the
Beta-blocker Evaluation of Survival Trial (BEST).
BACKGROUND Previous studies indicate that echocardiographic measurements of LV size and function,
mitral deceleration time, and mitral regurgitation (MR) predict adverse outcomes in HF.
However, complete quantitative echocardiograms evaluating all of these parameters have not
been reported in a prospective randomized clinical trial in the era of modern HF therapy.
METHODS Complete echocardiograms were performed in 336 patients at 26 sites and analyzed by a core
laboratory. A Cox proportional-hazards regression model was used to determine which
echocardiographic variables predicted the primary end point of death or the secondary end
point of death, HF hospitalization, or transplant. Significant variables were then entered into
a multivariable model adjusted for clinical and demographic covariates.
RESULTS On multivariable analysis adjusted for clinical covariates, only LV end-diastolic volume index
predicted death (events 75), with a cut point of 120 ml/m2. Three echocardiographic variables
predicted the combined end point of death (events 75), HF hospitalization (events 97), and
transplant (events  9): LV end-diastolic volume index, mitral deceleration time, and the vena
contracta width of MR. Optimal cut points for these variables were 120 ml/m2, 150 ms, and 0.4
cm, respectively.
CONCLUSIONS Echocardiographic predictors of outcome in advanced HF include LV end-diastolic volume
index, mitral deceleration time, and vena contracta width. These variables indicate that LV
remodeling, increased LV stiffness, and MR are independent predictors of outcome in
patients with advanced HF. (J Am Coll Cardiol 2005;45:1064–71) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.069American College of Cardiology Foundation
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fccording to the American College of Cardiology/
merican Heart Association practice guidelines, echocardi-
graphy is “the single most useful test in the evaluation of
atients with heart failure (HF)” (1). Among other things,
t offers the ability to assess chamber size, shape, and function,
lling pressures, pulmonary artery pressure, valvular disease,
ongenital abnormalities, and restrictive physiology (2). De-
pite its obvious clinical utility, it is difficult to demonstrate that
chocardiography influences patient outcomes or predicts re-
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004, accepted December 20, 2004.ponse to specific therapy (3). Although numerous variables
an be measured echocardiographically, it is not clear which of
hese variables predicts outcome in HF. In the Vasodilators in
eart Failure Trial (V-HeFT) (4), the Studies Of Left
entricular Dysfunction (SOLVD) (5), and the Valsartan in
eart Failure Trial (Val-HEFT) (6,7), echocardiographic
ssessment of left ventricular (LV) size and left ventricular
jection fraction (LVEF) predicted outcomes. However, these
tudies did not assess other echocardiographic variables, such as
itral deceleration time (8,9) or severity of mitral regurgitation
MR) (10), that have been shown in single-center or small
etrospective studies to predict outcome in HF. This study
eports the results of the Beta-blocker Evaluation of Survival
rial (BEST) echocardiographic substudy, in which we pro-
pectively sought to determine echocardiographic predictors of
utcome in patients with advanced HF due to severe LV
ystolic dysfunction in the absence of a reversible cause. We
ypothesized that baseline measurements of LV geometry and
unction, mitral deceleration time, and MR would predict
dverse outcomes independently of clinical covariates.
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he design and primary results of the BEST study have
een previously published (11). Briefly, patients with New
ork Heart Association (NYHA) functional class III or IV
F and LVEF35% were randomly assigned to placebo or
ucindolol therapy, with mortality as a primary end point.
atients were excluded if they had HF due to a reversible
ause, uncorrected primary valvular disease, hypertrophic
ardiomyopathy, untreated thyroid disease, pericardial dis-
ase, amyloidosis, active myocarditis, prosthetic valve dys-
unction, or recent myocardial infarction (6 months). All
atients were at least 18 years old and provided written,
nformed consent for the main trial and for the echocardio-
raphic substudy.
Complete two-dimensional and Doppler echocardio-
rams were performed in 355 patients enrolled in the BEST
tudy at 26 clinical sites. Sites were selected on the basis of
xperience in echocardiographic clinical research, interest in
his substudy, and submission of three protocol-specific
ualifying echocardiograms. All BEST participants at these
ites were asked to participate in the echocardiographic
ubstudy. Echocardiograms of poor technical quality were
xcluded in 19 patients (5%); the remaining 336 patients
omprise this report.
chocardiography. Blood pressure was taken by cuff at the
ime of echocardiography. A thorough two-dimensional
nd Doppler echocardiographic study was then performed
ccording to a specific imaging protocol. Each site received
training manual and videotape detailing the specific views
nd measurements required to assess LV systolic and dia-
tolic function, LV geometry, LV mass, and MR. All
chocardiographic data were recorded on S-VHS videotape
abeled with the date, BEST study patient identification
umber, and patient initials, and sent to the core laboratory
or analysis and quality control. Studies were interpreted
ithout knowledge of clinical characteristics or treatment
ssignment.
nalysis of LV systolic function and geometry. At each
articipating site, sonographers were instructed to adjust gain
ettings to optimize visualization of the LV endocardial con-
Abbreviations and Acronyms
BEST  Beta-blocker Evaluation of Survival Trial
CHF  congestive heart failure
EROA  effective regurgitant orifice area
HF  heart failure
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
MR  mitral regurgitation
NYHA  New York Heart Association
SAVE  Survival And Ventricular Enlargement trial
SOLVD  Studies Of Left Ventricular Dysfunction
trial
Val-HeFT Valsartan in Heart Failure Trialours while avoiding excessive gain artifact. Standard paraster- val, apical, and subcostal views were obtained. Specific instruc-
ion included placing the transducer as far laterally and caudally
s possible in the apical windows to maximize LV cavity size
nd avoid foreshortening. Technically difficult studies were
xcluded by the core laboratory when inadequate endocardial
order visualization in the apical views precluded measurement
f LV volumes. Left ventricular end-systolic and end-diastolic
imensions, posterior wall thickness, septal wall thickness, and
eft atrial dimension were measured according American So-
iety of Echocardiography recommendations (12). The LV
olumes and LVEF were quantified at the core laboratory
sing the biplane Simpson’s rule (12). Stroke volume and
ardiac output were determined by pulsed Doppler technique
s recommended by the American Society of Echocardiogra-
hy (13). The LV geometry was assessed by a ratio of the
ajor-to-minor axis at end-diastole (14) and as the sphericity
ndex, which is the ratio of the LV end-diastolic volume to a
phere whose radius equals the length of the LV (15). The LV
ass was assessed by the 5/6 area-length method as recom-
ended by the American Society of Echocardiography (12).
ircumferential wall stress was calculated from cuff systolic
lood pressure and end-systolic echocardiographic measure-
ents (16).
nalysis of LV diastolic function. Left ventricular filling
atterns were determined by pulsed Doppler technique with
1- to 2-mm sample volume positioned between the tips of
he mitral leaflets parallel to mitral inflow from the four-
hamber view (8,9). Mitral inflow patterns were analyzed
or maximal E and A velocities, E/A ratio, A-wave dura-
ion, and deceleration time. Deceleration time was calcu-
ated as the time between the peak E-wave and its deceler-
tion slope extrapolated to the zero baseline. By slightly
epositioning the sample volume to overlap mitral inflow
nd aortic outflow, isovolumic relaxation time was assessed
s the time from the end of aortic ejection to the start of
itral inflow. Pulmonary venous flow velocities were ob-
ained with a 2- to 4-mm sample volume positioned 1 to
cm into the right and left upper pulmonary veins from a
odified four-chamber view (13). Peak systolic and dia-
tolic flow velocities were recorded. In addition, the peak
-wave reversal and A duration were measured.
ssessment of MR. Doppler color flow mapping was used
o identify the presence or absence of MR. Gain settings were
ptimized by reducing the gain to the point where background
oise disappeared. Frame rate was maximized by minimizing
he sector angle and depth settings to allow visualization of the
ntire contour of the left atrium. The left atrium was interro-
ated from multiple acoustic windows using adjustments in
ransducer angulation to identify the largest MR velocity
rofile. The direction of the MR jet was assessed from both
arasternal and apical views, and the area of the largest clearly
efinable color flow disturbance was traced in each view as an
ndex of the severity of MR (17,18). The width of the jet vena
ontracta as it emerges from the valve leaflets was measured in
ach view (19). Quantitative Doppler assessment of regurgitant
olume, regurgitant fraction, and effective regurgitant orifice
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imilarly, the proximal isovelocity surface area method was also
sed to determine peak regurgitant flow rate and EROA (20).
n patients without MR, vena contracta width and EROA
ere considered to be 0 for purposes of statistical analysis.
inally, pulsed Doppler spectra from the pulmonary veins were
ssessed in a modified four-chamber view for systolic flow
eversal (20). All measurements of MR severity were made at
he core laboratory; results were sent to the data coordinating
enter where all statistical analysis was performed.
tatistical analysis. Continuous variables are reported as
ean  one standard deviation. Group comparisons were
ade by paired t test or Wilcoxon rank sum test, as
ppropriate. Categorical variables are reported as propor-
ions; comparisons were made by chi-square test or Fisher
xact test, as appropriate. The primary end point was death;
he secondary end point was death, transplant, or hospital-
zation for HF. Survival was determined by the Kaplan-
eier method and p values were calculated by the log-rank
est. All echocardiographic variables were assessed for uni-
ariate statistical significance using a Cox proportional
azard regression model. Variables with a p value0.1 were
hen entered into a multivariable model, which was adjusted
or the baseline covariates age, diabetes, creatinine, NYHA
unctional class, and treatment group. Optimal cut points
or variables that were predictive of outcome on multivari-
Table 1. Clinical Characteristics of Patients in
Treatment Assignment Compared to the BES
Pl
(n 
Demographics
Age (yrs) 61
Female 27
Caucasian 127
African American 31
Hispanic 7
Clinical variables
Heart rate (beats/min) 81
Systolic blood pressure (mm Hg) 118
Diastolic blood pressure (mm Hg) 71
NYHA functional class III 151
NHYA functional class IV 16
Diabetes mellitus 50
Hypertension 92
Prior CABG 47
Ischemic cardiomyopathy 99
Medications
ACE inhibitor 146
Angiotensin II antagonist 20
Digoxin 149
Diuretics 161
Vasodilators 81
Antiarrhythmic agent 3
ACE  angiotensin-converting enzyme; BEST  Beta-bloc
graft; NYHA  New York Heart Association.ble analysis were selected by examining box plots showing dhether or not an event occurred. For all analyses, a p value
0.05 was considered statistically significant.
ESULTS
able 1 compares the clinical characteristics of the patients
n the echocardiographic substudy, by treatment assigned, to
hose in the main BEST study. There were no significant
ifferences between patients in the echocardiographic sub-
tudy and those in the main trial, nor were there differences
etween substudy patients randomized to placebo and those
reated with bucindolol. There were no significant differ-
nces in the echocardiographic measurements between
roups (Table 2). In the 336 patients in the echocardio-
raphic substudy, baseline LVEF by multiple gated acqui-
ition was 22.7  7.7%, compared with 24.9  9.5% by
chocardiography (p  0.0001).
Of the 336 patients in the BEST echocardiographic
ubstudy, there were 75 (22%) deaths, 9 (3%) heart
ransplants, and 97 (29%) hospitalizations for congestive
eart failure (CHF). As shown in Table 3, several
chocardiographic variables predicted outcome by univar-
ate analysis. However, multivariable analysis showed that
nly three echocardiographic variables were predictors of
hese outcomes after adjustment for clinical covariates.
nly LV end-diastolic volume index was predictive of
BEST Echocardiographic Substudy by
hort
Echo Substudy
BEST Cohort
(n  2,708))
Bucindolol
(n  169)
60  13 60  12
) 37 (22%) 593 (22%)
) 117 (69%) 1,896 (70%)
) 42 (25%) 627 (23%)
7 (4%) 143 (5%)
82  13 81  13
115  18 117  18
69  11 71  11
) 156 (92%) 2,482 (92%)
) 13 (8%) 226 (8%)
) 54 (32%) 964 (36%)
) 91 (54%) 1,596 (59%)
) 52 (31%) 782 (29%)
) 91 (54%) 1,587 (59%)
) 157 (93%) 2,470 (91%)
) 11 (7%) 174 (6%)
) 152 (90%) 2,501 (92%)
) 159 (94%) 2,537 (94%)
) 72 (43%) 1,271 (47%)
5 (3%) 73 (3%)
aluation of Survival Trial; CABG  coronary artery bypassthe
T Co
acebo
167
 12
(16%
(76%
(19%
(4%)
 13
 18
 11
(90%
(10%
(30%
(55%
(28%
(59%
(87%
(12%
(89%
(96%
(49%
(2%)
ker Eveath on multivariable analysis. Figure 1 shows a Kaplan-
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V end-diastolic volume index 120 ml/m2. Left ven-
ricular end-diastolic volume index, mitral deceleration
ime, and vena contracta width (a marker of MR severity)
ere significant predictors of the combined end point of
eath, transplant, or hospitalization for CHF. Figure 2
hows the Kaplan-Meier event-free survival plots for
hese three variables using cut points of 120 ml/m2 for
able 2. Baseline Echocardiographic and Doppler Variables by
reatment Group
Placebo
(n  167)
Bucindolol
(n  169)
V end-diastolic dimension (cm) 6.6  0.9 6.7  0.9
V end-systolic dimension (cm) 5.8  0.9 5.9  1.0
eptal wall thickness (cm) 0.9  0.2 0.9  0.2
osterior wall thickness (cm) 1.0  0.2 0.9  0.2
A dimension (cm) 4.5  0.6 4.5  0.8
VOT diameter (cm) 2.2  0.2 2.2  0.2
itral annulus diameter (PLAX) (cm) 3.0  0.4 3.0  0.4
itral annulus diameter (4-chamber) (cm) 3.0  0.4 3.0  0.4
VOT velocity-time integral (cm) 13.2  4.2 12.7  3.9
ystolic ejection period (ms) 248  38 247  37
itral E velocity (m/s) 0.8  0.3 0.8  0.3
itral A velocity (m/s) 0.6  0.3 0.6  0.3
itral A wave duration (ms) 140  32 141  29
eceleration time (msec) 162  64 168  70
sovolumic relaxation time (ms) 97  31 96  33
itral annulus velocity-time integral (cm) 9.1  3.6 8.5  3.2
ulmonary vein S1 velocity (m/s) 0.3  0.1 0.3  0.1
ulmonary vein S2 velocity (m/s) 0.4  0.2 0.4  0.2
ulmonary vein D velocity (m/s) 0.5  0.2 0.5  0.2
ulmonary vein A velocity (m/s) 0.3  0.1 0.3  0.1
ulmonary vein A duration (ms) 139  27 144  26
ulmonary vein systolic flow reversal 10 (7%) 7 (6%)
ricuspid regurgitation peak velocity (m/s) 2.9  0.7 2.8  0.6
V end-diastolic volume index (ml/m2) 113  35 115  42
V end-systolic volume index (ml/m2) 85  31 88  40
VEF (%) 25  10 24  9
V mass index (g/m2) 144  36 146  43
ractional area shortening (%) 18  9 18  9
V length (cm) 9.6  1.0 9.5  1.0
phericity index 0.3  0.1 0.3  0.1
ajor-to-minor axis ratio 1.5  0.2 1.4  0.2
V end-systolic stress, meridional
(dynes/cm2)
153  65 146  67
V end-systolic stress, circumferential
(dynes/cm2)
542  406 563  419
R 124 (75%) 130 (78%)
R jet area (cm2) 9.0  5.4 9.3  5.8
R vena contracta width (cm) 0.4  0.1 0.3  0.1
R jet velocity-time integral (cm) 133  29 137  36
R jet peak velocity (m/s) 4.3  0.7 4.3  0.7
R jet dp/dt (mm Hg/s) 803  747 789  720
ISA radius (cm) 0.5  0.1 0.5  0.2
ROA, PISA (cm2) 0.2  0.1 0.1  0.1
ROA, quantitative Doppler (cm2) 0.1  0.1 0.0  0.1
egurgitant fraction, quantitative Doppler 0.1  0.4 0.1  0.5
ROA  effective regurgitant orifice area; LA  left atrial; LV  left ventricular;
VEF  left ventricular ejection fraction; LVOT  left ventricular outflow tract;
R  mitral regurgitation; PISA  proximal isovelocity surface area; PLAX 
arasternal long axis.V end-diastolic volume index, 150 ms for mitral
meceleration time, and 0.4 cm for MR vena contracta
idth.
Table 4 shows the echocardiographic and clinical predic-
ors of outcome by multivariable analysis. For all patients in
he echocardiographic substudy, LV end-diastolic volume
ndex, creatinine, and treatment group (bucindolol vs. pla-
ebo) were significant predictors of mortality. Predictors of
he combined end point included LV end-diastolic volume
ndex, mitral deceleration time, MR vena contracta width,
iabetes, creatinine, and treatment group.
ISCUSSION
lthough echocardiography is widely used to evaluate car-
iac structure and function in patients with HF, few data are
vailable regarding its ability to predict outcomes (21). A
arge number of variables can be measured or calculated by
chocardiographic and Doppler imaging, many of which are
hysiologically or even mathematically related. Thus, it is
ot clear which echocardiographic measurements provide
ndependent prognostic information. This substudy of the
EST study demonstrates that echocardiographic measures
f LV end-diastolic volume index, mitral deceleration time,
nd MR vena contracta width predict outcomes in patients
able 3. Echocardiographic Predictors of Outcomes on
nivariate Analysis
Variable n Death
Combined
End Point
VEF 335 0.0679
ractional area shortening 327 0.0097
sovolumic relaxation time 295
V end-diastolic dimension 336 0.0339 0.0130
V end-systolic dimension 336 0.0048 0.0034
V length 336 0.0854 0.0064
A dimension 335 0.0738 0.0462
V end-systolic stress, meridional 320 0.0060
V septal wall thickness 336 0.0789
V sphericity index 335 0.0344
V end-diastolic volume index 335 0.0015 0.0001
V end-systolic volume index 335 0.0018 0.0001
V mass index 327 0.0804 0.0046
VOT velocity-time integral 328 0.0207 0.0034
itral annulus diameter, 4-chamber 332 0.0378 0.0050
itral annulus diameter, long-axis 332 0.0736
itral E velocity 316 0.0233 0.0003
itral A velocity 282 0.0226 0.0001
itral A duration 279 0.0022
itral deceleration time 302 0.0464 0.0001
itral annulus velocity-time integral 293 0.0273 0.0518
R 332 0.0722
R vena contracta width 235 0.0996 0.0003
R PISA radius 220 0.0889 0.0078
R EROA, PISA 195 0.0609 0.0012
R EROA, volumetric 259 0.0001
R regurgitant fraction, volumetric 301 0.0515
R jet area 247 0.0002
R jet dp/dt 250 0.0535
R jet peak velocity 214 0.0007
nly parameters with p values 0.10 are shown. These were entered into the
ultivariable model.
Abbreviations as in Table 2.
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Echo Predictors of Mortality in Heart Failure April 5, 2005:1064–71ith advanced HF (NYHA functional class III or IV
ymptoms and LVEF 35%).
V end-diastolic volume index. Left ventricular volumes
re important predictors of outcome after acute myocardial
nfarction. White et al. (22) showed that LV end-systolic
olume index was an independent predictor of survival after
cute myocardial infarction. In the Survival And Ventricular
nlargement (SAVE) trial, LV cavity area, measured in a
hort-axis view, was reduced by captopril, and this reduction
as associated with improved outcomes (23). Moreover,
aseline LV cavity area predicted cardiovascular outcome
egardless of treatment assigned (24). The SAVE trial also
howed that LV remodeling after myocardial infarction was
ssociated with ventricular arrhythmias (25).
Echocardiographic LV volume data has also been reported
n HF clinical trials. In the SOLVD prevention and treatment
rms (26), enalapril significantly reduced LV end-diastolic
olume, LV end-systolic volume, and LV mass over 12 months
ompared with placebo in 301 patients enrolled in an echocar-
iographic substudy. Carvedilol has also been shown to reduce
V volumes and increase LVEF, in 123 patients in the
ustralia-New Zealand Heart Failure Research Collaborative
roup (27). The Val-HeFT echocardiographic substudy (6)
howed a reduction in LV end-diastolic dimension and an
ncrease in LVEF with valsartan therapy compared to placebo
n 5,010 patients. Although these studies showed favorable
ffects on LV remodeling of drugs known to improve survival
n HF, they did not report the relation of echocardiographic
ariables measured at baseline to outcomes in HF, nor did they
valuate other important echocardiographic variables such as
V filling velocities or MR severity. In this substudy of the
EST trial, LV end-diastolic volume index was the only
chocardiographic variable that predicted the primary outcome
f death when adjusted for clinical covariates.
Many echocardiography laboratories do not measure LV
olumes, but instead rely on LV dimensions, in part because
igure 1. Kaplan-Meier plot showing time to death by left ventricular (LV)
olume index 120 ml/m2 versus 120 ml/m2. E  events.f their ease of measurement and many years of clinical aamiliarity. In this study, LV dimensions were predictive of
eath and the combined end point on univariate, but not on
ultivariable, analysis. Recent studies using contrast echo-
ardiography have shown that the accuracy of LV volumes
s improved in technically difficult patients by the use of
ontrast (28,29), thus enabling measurement of LV volumes
nd LVEF in nearly all patients. The present data support
outine measurement and reporting of LV volumes by
chocardiography in patients with HF. Moreover, the prog-
ostic importance of LV end-diastolic volume index high-
ights the interest in newer surgical techniques to reduce LV
olumes in ischemic cardiomyopathy (30). A large clinical
rial has been initiated to determine whether reducing LV
olumes by surgical ventricular restoration will improve
ortality in HF (31).
itral deceleration time. This study confirms the results of
revious single-center studies that showed that mitral deceler-
tion time predicts outcome in HF (8,9,32,33). In this large,
ulticenter trial of patients with advanced HF, mitral decel-
ration time independently predicted the combined end point
f death, heart failure hospitalization, or transplant. The
ptimal cut point for mitral deceleration time was 150 ms. The
athophysiologic basis for this finding is that mitral decelera-
ion time is a marker of increased LV stiffness (34) and
ecreased myocardial viability (35), factors associated with
xtensive fibrosis and necrosis.
R vena contracta width. Functional MR is a common
omplication of ischemic heart disease and is widely considered
o contribute to symptoms and mortality. Two large clinical
rials have shown that functional MR occurring either early or
ate (16 days) after acute myocardial infarction is associated
ith increased mortality (36,37). However, until recently,
tudies in dilated cardiomyopathy were small and limited
ainly to nonischemic etiology (10,38–40). A recent retro-
pective study by Trichon et al. (41) reported that the angio-
raphic severity of MR predicts mortality in patients with HF
iastolic volume index. Patients are stratified according to LV end-diastolicnd LVEF40%. This study confirms the prognostic impor-
F
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April 5, 2005:1064–71 Echo Predictors of Mortality in Heart Failureigure 2. Kaplan-Meier plots showing time to the combined end point of death, heart failure hospitalization, or transplant for patients with a left ventricular
nd-diastolic volume index (LVEDVI) 120 ml/m2 versus 120 ml/m2 (top panel), a mitral deceleration time (DT) 150 ms versus 150 ms (middle
anel), and a mitral regurgitation vena contracta width (VCW) of 0.4 cm versus 0.4 cm (bottom panel). Variables included in the model were
VEDVI, mitral DT, and mitral regurgitation VCW. E  events.
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Echo Predictors of Mortality in Heart Failure April 5, 2005:1064–71ance of MR in advanced HF in a prospective clinical trial.
lthough several echocardiographic measures of MR severity
redicted the combined end point on univariate analysis, only
ena contracta width remained predictive on multivariable
nalysis, even when adjusted for clinical covariates. Patients
ith a vena contracta width 0.4 cm had a greater likelihood
f death, transplant, or HF hospitalization. Importantly, a vena
ontracta of 0.4 cm is generally considered to be only moderate
R (19).
tudy limitations. The patients in this substudy were not
andomly selected from all eligible patients in the BEST study.
nstead, they were enrolled from expert sites, which underwent
pecific training in the acquisition of this study protocol.
lthough this method assured high-quality data, we cannot be
ertain that these results apply to the overall BEST study
opulation. In fact, the finding that treatment with bucindolol
redicted improved survival in this substudy indicates that
hese patients are not representative of the overall BEST study
opulation, because bucindolol was not associated with a
urvival benefit in the main trial. Moreover, because this study
as initiated in 1996, tissue Doppler, strain-rate imaging,
armonic imaging, and contrast agents were not used. Finally,
VEF was predictive of outcome on univariable, but not on
ultivariable, analysis. This differs from prior studies (4–7).
ikely reasons include the narrow and limited range of LVEF
n this substudy, a relatively small number of patients, and the
act the LV end-diastolic volume, which was a statistically
ignificant predictor, is a mathematical determinant of LVEF.
onclusions. Echocardiographic predictors of outcome in
dvanced HF include LV end-diastolic volume index, mitral
eceleration time, and vena contracta width. These variables
ndicate that LV remodeling, increased LV stiffness, and
R severity are independent predictors of outcome in
able 4. Predictors of Outcome on Cox Proportional Hazards
ultivariable Analysis Adjusted for Baseline Covariates
Primary End Point of Death (E  75)*
Baseline Variable HR 95% CI p Value
V end-diastolic volume index 1.009 1.003–1.014 0.0012
reatinine 2.023 1.235–3.316 0.0052
reatment group 0.566 0.355–0.902 0.0167
Secondary End Point of Death (E  75),
HF Hospitalization (E  97), or Transplant (E  9)†
Baseline Variable HR 95% CI p Value
V end-diastolic volume index 1.009 1.004–1.015 0.0008
itral deceleration time 0.992 0.987–0.997 0.0014
R vena contracta width 10.669 2.331–48.823 0.0023
reatinine 1.921 1.182–3.123 0.0085
istory of diabetes 1.599 1.024–2.496 0.0390
reatment group 0.503 0.326–0.775 0.0018
Seven initial covariates entered into model: LV end-diastolic volume index, history
f diabetes, creatinine, age, gender, NYHA functional class, treatment group. †Nine
nitial covariates entered into model: LV end-diastolic volume index, mitral deceler-
tion time, MR vena contracta width, history of diabetes, creatinine, age, gender,
YHA functional class, treatment group.
CI  confidence interval; E  events; HF  heart failure; HR  hazard ratio;
ther abbreviations as in Tables 1 and 2.atients with advanced HF.eprint requests and correspondence: Dr. Paul A. Grayburn,
aylor Heart and Vascular Institute, Baylor University Medical
enter, 621 North Hall Street, Dallas, Texas 75226. E-mail:
aulgr@baylorhealth.edu.
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or a list of participants in the BEST Echocardiographic
ubstudy, please see the April 5, 2005, issue of JACC at
ttp://www.onlinejacc.org.
